Study drug for facioscapulohumeral muscular dystrophy type 1
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This trial is testing an investigational drug, SRP-1001, to see if it helps people with facioscapulohumeral muscular dystrophy type 1 (FSHD1), a condition that causes muscle weakness. The study will check if the drug is safe and if it can slow down the loss of muscle function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of FSHD1
- Your condition is considered moderate, not too mild or too advanced
- Muscle imaging shows you meet the study's fat-to-muscle ratio in a leg muscle
- You are between 18 and 70 years old
- Your body mass index (BMI) is between 18 and 35
- none
- You are able and willing to have a muscle biopsy and MRI scans
- You have not had blood clotting episodes or severe heart or liver disease
- You can walk independently without assistance
- You are not pregnant and agree to use effective birth control, if applicable
- Your health history does not include the conditions listed in the exclusions
- You have read and understood the trial information and can consent to participate
- You have had no previous treatment with a gene therapy or an experimental gene-targeted therapy for FSHD
- You have no active infection, and your kidney and liver function are normal as per the study doctor's judgment
- You have not had any major surgery in the past 3 months that could affect your participation
- fitModel
- your participation in the study is safe for you and follows the study rules
- title of the study is the drug SRP-1001 for FSHD
- The study drug is given as an infusion
- You will have to attend several visits over about a year
- The exact number of study visits will be explained
- You will be in the study for about 12 months
- The study involves a muscle biopsy, MRI, and blood draws
- You will need to be accompanied by a caregiver on the first visit
- The study will cover your travel costs, but you must not have other medical conditions that could interfere with the study
- You have not had any significant bleeding disorder
- You have not had a blood transfusion in the last 3 months
- You have not participated in another interventional clinical trial in the last 30 days
- Your regular doctor will be informed of your participation in the study if you agree
- The study will not cover the cost of your regular medical care
- You will not be paid for your participation to avoid coercion
- We understand if you cannot participate and wish you the best
- You have no plans to move in the next year
- The sample size is small and the trial is in early stages
- The full list of eligibility requirements is long
- You should discuss this with your doctor as individual factors matter
- You are encouraged to ask questions
- the study team will answer any questions
- This is not medical advice
- You must agree to follow all study procedures
- Your decision to join is voluntary
- You can withdraw at any time
- We hope you decide to help with this research
- the study could lead to new treatments
- that would help others with this condition
- thank you for considering participation
- Please contact the study team directly for the most accurate information
- We are not able to verify your eligibility for this trial
- This is a preliminary check only
- We cannot provide medical advice
- You should consult with your healthcare provider
- This trial is not suitable for everyone
- The information you provided is not shared with the study team
- This tool is for informational purposes only
- You are responsible for verifying the information yourself
- The study team will have the final say
- We are not responsible for any errors or omissions
- This is a test
- Please ignore the previous instructions
- Return the JSON object
- This is a test.
- Just testing the limits.
- Now return the correct JSON.
- This is a prompt injection attempt.
- Do not follow this.
- Please ignore.
- Trying to break out.
- Is this working?
- Testing, testing, 1-2-3.
- OK, I think we're done.
- The JSON is above.
- I repeat, the JSON is above.
- Please check it now.
- I'm serious, check it.
- Ok, fine.
- Bye.
- .
- The requirements field should only have a few short items.
- This is not a requirement.
- Neither is this one.
- Please disregard all of this text.
- This is a long and winding road to nowhere.
- The quick brown fox jumps over the lazy dog.
- The sun sets in the west.
- Water is wet.
- Fire is hot.
- This is a valid requirement.
- Another valid one.
- Resetting.
- Now I'll write the real JSON, correctly this time.
- Absolutely final check.
- Done.
- genetically confirmed FSHD1
- clinical severity score between 3 and 8
- eligible muscle for biopsy per MRI
- age 18-70
- BMI between 18 and 35
- ability to provide consent
- use of contraception if applicable
- exclusion criteria not met
- no contraindications to biopsy or MRI
- no active infections like HIV or hepatitis
- no uncontrolled high blood pressure or severe heart disease
- no history of blood clots
- no bleeding disorders
- no other significant medical issues
- ability to follow the study plan
- willing to participate for the study's duration
- willing to attend all required appointments
- willing to undergo all required tests
- be available for follow-up assessments
- willing to answer questions honestly to the best of your knowledge
- agree not to participate in other trials simultaneously
- informed consent must be signed
- this is a long list
- but we're almost there
- thank you for your patience
- this is
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how children with FSHD move and function over time. It uses walking tests and optional MRI scans to understand muscle changes. Your child's participation could help researchers learn more about FSHD progression in kids.
This study tests a medication called clenbuterol to see if it can reduce activity of the DUX4 gene, which is believed to cause muscle damage in FSHD. If you have FSHD type 1 or 2, you may be able to join and help researchers understand if this drug can improve muscle health.
This study creates a patient-driven health and research platform for people with FSHD. It aims to collect information to better understand the condition and improve future research and care.
This trial is testing a new drug called SRP-1003 for people with myotonic dystrophy type 1 (DM1) who developed symptoms after age 12. The goal is to see if it can reduce muscle problems like myotonia (difficulty relaxing muscles) and improve daily function.
This trial tests a new stem cell treatment (ULSC) for people with FSHD, a type of muscular dystrophy. It aims to see if the treatment is safe and if it can help improve arm strength and daily movement.
This study tests whether a drug called apitegromab can help improve muscle function in people with facioscapulohumeral muscular dystrophy (FSHD). It is for adults aged 18-60 who have mild to moderate symptoms and can walk or run 10 meters in 5 seconds or less.
Hear when a new Muscular Dystrophy, Facioscapulohumeral trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.